Table 1 Characteristics of patients with Gastroenteropancreatic Neuroendocrine Tumors and of their initial treatments, SEER-Medicare 1995–2010; Small Intestine Not Otherwise Specified: SI NOS; National Cancer Institute: NCI
Characteristic | low (n = 331) | medium (n = 408) | high (n = 160) | p-value |
|---|---|---|---|---|
Mean age (SD) | 75.1 (7.3) | 73.8 (7.1) | 73.0 (6.2) | 0.023 |
Median time to treatment (SD) | 22.0 (47.5) | 24.0 (41.8) | 26.0 (55.1) | 0.148 |
Male, n (%) | 150 (45.3) | 185 (45.3) | 78 (48.8) | 0.734 |
Race, n (%) | 0.799 | |||
white | 280 (84.6) | 344 (84.3) | 137 (85.6) | |
black | 26 (7.9) | 38 (9.3) | > 12 (> 7.5) | |
other | 25 (7.6) | 26 (6.4) | < 11 (< 6.9) | |
Primary site, n (%) | <.0001 | |||
stomach | 37 (11.2) | 37 (9.1) | < 11 (< 6.9) | |
duodenum | 11 (3.3) | > 11 (> 2.7) | 15 (9.4) | |
jejunum/ileum | 38 (11.5) | 77 (18.9) | 38 (23.8) | |
SI NOS* | 23 (7.0) | 40 (9.8) | 13 (8.1) | |
appendix | < 11 (< 3.3) | < 11(< 2.7) | < 11 (< 6.9) | |
cecum | 71 (21.5) | 71 (17.4) | 13 (8.1) | |
colon | 80 (24.2) | 77 (18.9) | 25 (15.6) | |
rectum | 52 (15.7) | 42 (10.3) | < 11 (< 6.9) | |
pancreas | < 11 (< 3.3) | 40 (9.8) | 26 (22.5) | |
Tumor stage, n (%) | 0.0009 | |||
local | 58 (17.5) | 73 (17.9) | 51 (31.9) | |
regional | 135 (40.8) | 186 (45.59) | 56 (35.0) | |
distant | 138 (41.7) | 149 (36.5) | 53 (33.1) | |
Tumor differentiation, n (%) | <.0001 | |||
well-differentiated | 82 (24.8) | 167 (40.9) | 107 (66.9) | |
moderately-differentiated | 70 (21.2) | 74 (18.1) | 19 (11.9) | |
poorly-differentiated | 179 (54.1) | 167 (40.9) | 34 (21.3) | |
Comorbidity, n (%) | 0.815 | |||
0 | 138 (41.7) | 166 (40.7) | 63 (39.4) | |
1–2 | 142 (42.9) | 169 (41.4) | 73 (45.6) | |
3+ | 51 (15.41) | 73 (17.9) | 24 (15.0) | |
Treatment type, n (%) | <.0001 | |||
surgery | 223 (67.4) | 331 (81.1) | 145 (90.6) | |
endoscopy | 21 (6.3) | 16 (3.9) | < 11 (< 6.9) | |
chemotherapy | 25 (7.6) | 20 (4.9) | < 11 (< 6.9) | |
radiation therapy | 12 (3.6) | < 11 (< 2.7) | < 11 (< 6.9) | |
somatostatin analogue | 35 (10.6) | 14 (3.4) | < 11 (< 6.9) | |
surgery and additional treatment(s) | 15 (4.5) | > 16 (> 3.9) | < 11 (< 6.9) | |
NCI designated cancer center*, n (%) | ||||
yes | < 11 (< 3.3) | < 11 (< 2.7) | 16 (10.0) | |
no | 308 (93.1) | 383 (93.9) | 123 (76.9) | |
unknown | > 12 (> 3.6) | > 14 (> 3.4) | 21 (13.1) | |
<.0001 | ||||
Academic center*, n (%) | ||||
yes | 143 (43.2) | 252 (61.8) | 131 (81.9) | |
no | 173 (52.3) | > 145 (> 35.5) | > 18 (> 11.3) | |
unknown | 15 (4.5) | < 11 (< 2.7) | < 11 (< 6.9) | |
<.0001 |